Portal de Periódicos da CAPES

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

2020; American Association for the Advancement of Science; Volume: 12; Issue: 549 Linguagem: Inglês

10.1126/scitranslmed.aba2325

1946-6242

Janelle Waite, Bei Wang, Lauric Haber, Aynur Hermann, Erica Ullman, Xuan Ye, Drew Dudgeon, Rabih Slim, Dharani K. Ajithdoss, Stephen Godin, Ilyssa Ramos, Qi Wu, Erin Oswald, Patrick Poon, Jacquelynn Golubov, Devon Grote, Jennifer Stella, Arpita Pawashe, Jennifer Finney, Evan Herlihy, Hassan Ahmed, Vishal Kamat, Amanda D’Orvilliers, Elizabeth Navarro, Jenny Xiao, Julie Kim, Shao Ning Yang, Jacqueline J. Warsaw, Clarissa Lett, Lauren Canova, Teresa Schulenburg, Randi Foster, Pamela Krueger, Elena Garnova, Ashique Rafique, Robert Babb, Gang Chen, Nicole Stokes Oristian, Chia-Jen Siao, Christopher Daly, Cagan Gurer, Joel Martin, Lynn E. Macdonald, Douglas MacDonald, William Poueymirou, Eric Smith, Israel Lowy, Gavin Thurston, William C. Olson, John Lin, Matthew A. Sleeman, George D. Yancopoulos, Andrew Murphy, Dimitris Skokos,

Immunotherapy and Immune Responses

Antibodies cross-linking the CD28 costimulatory pathway and a target antigen on tumors potentiate the effects of checkpoint immunotherapy.